IP Library Granted Patent US 11,859,247
Granted Patent B2
US 11,859,247 · App. 17/355,668 · Granted Jan 2, 2024

Enzyme-pore constructs

Inventors: Lakmal Jayasinghe (Oxford, GB); John Hagan Pryce Bayley (Oxford, GB); Stephen Cheley (East Lansing, MI); Brian McKeown (Middle Barton Oxon, GB); James White (Oxford, GB); James Clarke (Oxford, GB)
Assignee: Oxford Nanopore Technologies PLC
C12Q1/6869C07K14/31C12N9/127C12N9/1247C12N9/1252C12N9/1276C12N9/16C12N9/22C12N9/52C12N9/90C12N9/96
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,859,247
App. No.
17/355,668
Granted
Jan 2, 2024
Kind
B2
Abstract

The invention relates to constructs comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme. The pore subunit is covalently attached to the enzyme such that both the subunit and enzyme retain their activity. The constructs can be used to generate transmembrane protein pores having a nucleic acid handling enzyme attached thereto. Such pores are particularly useful for sequencing nucleic acids. The enzyme handles the nucleic acid in such a way that the pore can detect its component nucleotides by stochastic sensing.

Claims (14)

1. A method of purifying a transmembrane pore comprising at least one transmembrane construct, the transmembrane construct comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme, wherein the subunit is covalently attached to the enzyme, wherein the subunit retains its ability to form a pore and wherein the enzyme retains its ability to handle nucleic acids, said method comprising:

(a) providing the at least one construct and other subunits required to form the pore;

(b) oligomerising the at least one construct and other subunits on lipid vesicles;

(c) contacting the vesicles with a non-ionic surfactant; and

(d) recovering the oligomerised pore.

2. The method according to claim 1 , wherein the lipid vesicles in (b) are synthetic lipid vesicles.

3. The method according to claim 1 , wherein step (d) comprises recovering the oligomerised pore by liquid chromatography.

4. The method according to claim 1 , wherein after steps (a) to (d) the oligomerised pore is substantially pure and in a form that comprises less than 10% of other components.

5. The method according to claim 1 , wherein after steps (a) to (d) the oligomerised pore is substantially pure and in a form that comprises less than 5% of other components.

6. The method according to claim 1 , wherein after steps (a) to (d) the oligomerised pore is substantially pure and in a form that comprises less than 2% of other components.

7. The method according to claim 1 , wherein the nucleic acid handling enzyme is a polymerase, exonuclease, helicase or topoisomerase.

8. The method according to claim 1 , wherein the transmembrane protein pore subunit is from a β-barrel pore or an α-helix pore.

9. The method according to claim 1 , wherein the transmembrane protein pore subunit is from α-hemolysin.

10. The method according to claim 1 , wherein the transmembrane pore comprises 6, 7 or 8 transmembrane protein pore subunits.

Assignments (2)
CHANGE OF NAME Recorded Jan 14, 2022
From: OXFORD NANOPORE TECHNOLOGIES LIMITED
To: OXFORD NANOPORE TECHNOLOGIES PLC
Reel/Frame 058737/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2021
From: JAYASINGHE, LAKMAL; BAYLEY, JOHN HAGAN PRYCE; CHELEY, STEPHEN; MCKEOWN, BRIAN; WHITE, JAMES; CLARKE, JAMES ANTHONY
To: OXFORD NANOPORE TECHNOLOGIES LIMITED
Reel/Frame 056664/0022 →
Continuity (6)
Continuation 16129693 · Sep 12, 2018
Continuation 14858138 · Sep 18, 2015
Division 14455394 · Aug 8, 2014
Division 13002709
Provisional Application 61078695 · Jul 7, 2008
Related Publication 20220064722A1 · Mar 3, 2022